Impact of Nelfinavir Resistance Mutations on In Vitro Phenotype, Fitness, and Replication Capacity of Human Immunodeficiency Virus Type 1 with Subtype B and C Proteases
Open Access
- 1 September 2004
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (9) , 3552-3555
- https://doi.org/10.1128/aac.48.9.3552-3555.2004
Abstract
Human immunodeficiency virus type 1 subtype B and C proteases were manipulated to contain 90M, 88D, or 89L, and their in vitro biological properties were studied. We showed that D30N has significantly more impact in subtype C than in subtype B counterparts, accounting for the reported low prevalence of this mutation in patients failing nelfinavir-based regimens.Keywords
This publication has 22 references indexed in Scilit:
- Parameters Driving the Selection of Nelfinavir-Resistant Human Immunodeficiency Virus Type 1 VariantsJournal of Virology, 2003
- In Vitro Hypersusceptibility of Human Immunodeficiency Virus Type 1 Subtype C Protease to LopinavirAntimicrobial Agents and Chemotherapy, 2003
- Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor TreatmentsJournal of Virology, 2003
- Changes in the Human Immunodeficiency Virus p7-p1-p6 gag Gene in Drug-Naive and Pretreated PatientsJournal of Clinical Microbiology, 2003
- Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapyJournal of Medical Virology, 2002
- Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive personsProceedings of the National Academy of Sciences, 2001
- Resistance to Nucleoside Analog Reverse Transcriptase Inhibitors Mediated by Human Immunodeficiency Virus Type 1 p6 ProteinJournal of Virology, 2001
- Resistance-Associated Mutations in the Human Immunodeficiency Virus Type 1 Subtype C Protease Gene from Treated and Untreated Patients in the United KingdomJournal of Clinical Microbiology, 2001
- Human Immunodeficiency Virus Type 1 Protease Cleavage Site Mutations Associated with Protease Inhibitor Cross-Resistance Selected by Indinavir, Ritonavir, and/or SaquinavirJournal of Virology, 2001
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998